Login

Journal Image
Central Nervous System Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Central Nervous System Agents)
ISSN (Print): 1871-5249
ISSN (Online): 1875-6166
Epub Full Text Article
DOI: 10.2174/1871524914999140818111514      Price:  $95









Novel Agents in CNS Myeloma Treatment

img
Author(s): Alessandro Gozzetti and Alfonso Cerase
Abstract:
Central nervous system localization of multiple myeloma (CNS-MM) accounts for about 1% of all MM. Treatment is still unsatisfactory. Many treatments have been described in the literature: chemotherapy (CHT), intrathecal therapy (IT), and radiotherapy (RT), with survivals reported between one month and six months. Recent drugs such as the immunomodulatory drugs (IMiDs) and proteasome inhibitors (bortezomib) have changed the treatment of patients with MM, both younger and older, with a significant improvement in response and survival. The activity of new drugs in CNSMM has been reported but is still not well known. Bortezomib does not cross the blood brain barrier (BBB), and IMID’s seem to have only a minimal crossover. The role of novel agents in CNS MM management will be discussed as well as the potential role of other new immunomodulatory drugs (pomalidomide) and proteasome inhibitors that seem to cross the BBB and hold promise into the treatment of this rare and still incurable localization of the disease.
Keywords:
Bortezomib, chemotherapy, CNS, extramedullary myeloma, IMID’s, new agents
Affiliation:
Hematology, Azienda Ospedaliera Universitaria Senese, Policlinico “Santa Maria alle Scotte”, Viale Bracci 16, 53100 Siena, Italy